DUBLIN–(BUSINESS WIRE)–The “Discovery Stage Partnering Terms and Agreements in Pharma and Biotech 2020-2025” report has been added to ResearchAndMarkets.com’s offering.
This report contains a comprehensive listing of all discovery-stage partnering deals announced since 2020, including financial terms where available. It also features over 2,473 links to detailed online deal records, including publicly available contract documents filed with the SEC.
The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report offers a comprehensive, data-driven analysis of how and why companies engage in discovery-stage partnering deals and the financial and strategic terms underpinning these agreements. This essential industry resource provides deep insights into the structure, negotiation dynamics, and financial considerations that define early-stage partnerships in the pharmaceutical and biotech sectors.
Gaining insight into the flexibility and negotiation strategies of potential partners is crucial in structuring a successful discovery-stage deal. While headline financial terms (e.g., upfront payments, milestones, and royalties) provide a broad overview, contract documents offer a deeper understanding of the actual triggers and conditions for these payments – critical details that press releases and traditional databases often omit.
At the discovery stage, licensing agreements typically grant the licensee rights or options to further develop a licensor’s product or technology. These agreements are often multi-component, beginning with collaborative research and development (R&D) and potentially leading to commercialization agreements.
This report provides a detailed breakdown of the latest discovery-stage agreements in the healthcare sector, helping companies identify market trends, evaluate competitive deal structures, and optimize their own negotiation strategies.
A Must-Have Resource for Biotech and Pharma Dealmakers
The Global Discovery Stage Partnering Terms and Agreements in Pharma and Biotech (2020-2025) report is an indispensable resource for business development, legal, and financial professionals involved in biopharma dealmaking.
Critical Questions Answered
- What specific rights are granted in each agreement?
- What exclusivity terms apply?
- How is the deal structured financially? (Upfronts, milestones, royalties)
- How are sales and payments audited?
- Who controls development, manufacturing, and commercialization?
- How is intellectual property handled?
- How are confidentiality and publication rights managed?
- Under what conditions can a deal be terminated?
- What dispute resolution mechanisms are in place?
- What happens in the event of a change in ownership?
With comprehensive insights, a vast deal database, and direct access to contract documents, this report serves as the ultimate tool for:
- Benchmarking deal structures and financial terms
- Optimizing negotiation strategies
- Assessing potential partners’ flexibility and deal-making behavior
- Identifying trends and best practices in discovery-stage partnerships
Key Benefits of the Report
- Comprehensive insights into discovery-stage deal trends since 2020
- Access to key financial terms, including headline values, upfronts, milestones, and royalty structures
- Breakdown of deal structures, with real-world case studies
- Analysis of contractual terms, including real-world clause examples
- Benchmarking of deal terms based on actual agreements
- Due diligence insights to assess the suitability of proposed deal terms for potential partners
Scope of the Report
- Analysis of discovery-stage dealmaking trends in the biopharma industry since 2020
- Insight into financial structures, including upfront, milestone, and royalty payments
- Case studies of real-life discovery-stage agreements
- Access to over 2,690 discovery-stage deals, with contract records where available
- Profiles of the most active discovery-stage dealmakers since 2020
Each deal record is indexed by:
- Company (A-Z)
- Headline Value
- Stage of Development at Signing
- Deal Type
- Specific Therapy Focus
Key Topics Covered:
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Why do companies partner at discovery stage?
2.1. Introduction
2.2. The role of discovery stage partnering
2.2.1. In-licensing at discovery stage
2.2.2. Out-licensing at discovery stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into discovery stage partnering deals
2.4.1. Licensors reasons for entering discovery stage deals
2.4.2. Licensees reasons for entering discovery stage deals
2.5. The future of discovery stage partnering deals
Chapter 3 – Discovery stage deal strategies and structure
3.1. Introduction
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical/biotech
3.2.1.1. Discovery and preclinical stage partnering case studies
3.2.2. Partnering later in pharmaceutical/biotech
3.2.2.1. Clinical stage partnering case studies
3.3. Early and later stage partnering – a risk/cost comparison
3.4. What do companies spend on discovery, preclinical and clinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure licensing agreements
3.7. Multicomponent discovery stage partnering agreements
3.7.1.a. Example multicomponent early stage clauses
Chapter 4 – Discovery stage partnering payment strategies
4.1. Introduction
4.2. Discovery stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
4.3.2.1. Conditionality of upfront payments
4.3.3. Loans
4.3.4. Convertible loans
4.3.5. Equity
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
4.3.9.1. Issues affecting royalty rates
4.3.9.2. Royalties on combination products
4.3.9.3. Guaranteed minimum/maximum annual payments
4.3.9.4. Royalty stacking
4.3.9.5. Royalties and supply/purchase contracts
4.3.10. Quids
4.3.11. Option payments
Chapter 5 – Trends in discovery stage deal making
5.1. Introduction
5.2. Discovery stage partnering over the years
5.2.1. Attributes of discovery deals
5.3. Discovery stage partnering by deal type
5.4. Discovery stage partnering by disease type
5.5. Partnering by discovery stage technology type
5.6. Discovery stage partnering by most active company, 2020 to 2025
Chapter 6 – Payment terms for discovery stage partnering
6.1. Introduction
6.2. Guidelines for discovery stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Discovery stage payment terms – deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Discovery stage headline values
6.4.2. Discovery stage deal upfront payments
6.4.3. Discovery stage deal milestone payments
6.4.4. Discovery stage royalty rates
Chapter 7 – Leading discovery stage deals
7.1. Introduction
7.2. Top discovery stage deals by value
Chapter 8 – Top 25 most active discovery stage dealmakers
8.1. Introduction
8.2. Top 25 most active discovery stage dealmakers
Chapter 9 – Discovery stage partnering contracts directory
9.1. Introduction
9.2. Discovery stage deals with contracts 2020 to 2025
Chapter 10 – Discovery stage deal making by development stage
10.1. Introduction
10.2. Deals by discovery stage
Appendices
Appendix 1 – Discovery stage dealmaking by companies A-Z
Appendix 2 – Discovery stage dealmaking by industry sector
Appendix 3 – Discovery stage dealmaking by stage of development
Appendix 4 – Discovery stage dealmaking by therapy area
Appendix 5 – Discovery stage dealmaking by technology type
For more information about this report visit https://www.researchandmarkets.com/r/hhc4or
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900